Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI  853520

ConclusionsThese studies demonstrate that BI  853520 can be given with no food restrictions, and as a liquid dispersion, without strongly impacting pharmacokinetics. These pharmacokinetic properties may help make BI 853520 dosing more convenient and flexible, improving treatment compliance.Clinical trials registrationClinicalTrials.gov identifier: NCT01335269.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research